Marina Biotech (OTCMKTS:MRNA) Downgraded by Zacks Investment Research
According to Zacks, “Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company’s product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA- 2752 for Relapsed/Refractory solid tumors malignancies. Moderna Inc. is based in Cambridge, United States. “
Several other brokerages also recently weighed in on MRNA. Chardan Capital restated a buy rating and issued a $40.00 target price on shares of Marina Biotech in a research note on Sunday, June 2nd. Oppenheimer set a $13.00 target price on shares of Alpine Immune Sciences and gave the company a buy rating in a research note on Tuesday, March 19th. Finally, Piper Jaffray Companies decreased their target price on shares of Apyx Medical to $7.00 and set an overweight rating for the company in a research note on Wednesday, May 8th. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $27.10.
Marina Biotech (OTCMKTS:MRNA) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.01). The firm had revenue of $16.03 million for the quarter, compared to analyst estimates of $33.59 million.
Several large investors have recently modified their holdings of MRNA. Parallel Advisors LLC acquired a new stake in shares of Marina Biotech during the first quarter worth $207,000. Moloney Securities Asset Management LLC acquired a new stake in shares of Marina Biotech during the first quarter worth $1,051,000. Finally, Bainco International Investors acquired a new stake in shares of Marina Biotech during the first quarter worth $224,000.
Marina Biotech Company Profile
Marina Biotech, Inc, a biopharmaceutical company, engages in the development and commercialization of proprietary drug therapeutics primarily for hypertension, arthritis, pain, and oncology in the United States, Europe, and internationally. The company offers Prestalia, a single-pill fixed dose combination (FDC) of perindopril argenine, an angiotensin-converting-enzyme inhibitor; and amlodipine besylate, a calcium channel blocker for the treatment of hypertension.
Featured Story: What are the benefits of a portfolio tracker?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Marina Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marina Biotech and related companies with MarketBeat.com's FREE daily email newsletter.